Arca
Skip to content
Tools
Tools

ALOX5: Polyunsaturated fatty acid 5-lipoxygenase

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the oxygenation of arachidonate ((5Z,8Z,11Z,14Z)- eicosatetraenoate) to 5-hydroperoxyeicosatetraenoate (5-HPETE) followed by the dehydration to 5,6- epoxyeicosatetraenoate (Leukotriene A4/LTA4), the first two steps in the biosynthesis of leukotrienes, which are potent mediators of inflammation.

  • Drugs that act on it: 8
  • Approved: 6
  • In phases 1 to 3: 2
  • Sponsors: 5

Who Is On It, and How Far Along

Every drug ChEMBL records acting on ALOX5, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved6

  • Mesalamine
  • Sulfasalazine
  • Meclofenamic acid
  • Zileuton
  • Balsalazide
  • Olsalazine

Phase 30

    Phase 22

    • Atreleuton
    • PF-4191834

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Tallikut Pharmaceuticals, Inc.113%

      Modalities

      Drugs on this target by ChEMBL molecule type.

      • Small molecule8100%

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Arachidonate 5-lipoxygenase inhibitor.
      MesalamineApprovedViatrisSmall moleculeInhibitor—28—
      SulfasalazineApprovedPfizerSmall moleculeInhibitor—19—
      Meclofenamic acidApproved—Small moleculeInhibitor—2Boxed warning
      ZileutonApprovedChiesi GroupSmall moleculeInhibitor—1—
      BalsalazideApprovedBausch HealthSmall moleculeInhibitor—0—
      OlsalazineApprovedViatrisSmall moleculeInhibitor—0—
      AtreleutonPhase 2Tallikut Pharmaceuticals, Inc.Small moleculeInhibitor—0—
      PF-4191834Phase 2PfizerSmall moleculeInhibitor—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 19 in all, from ClinicalTrials.gov.
      Zileuton for Food AllergyZileutonPhase 1RecruitingAbigail Lang2026-11-13
      Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung DiseaseSulfasalazine—RecruitingPeking University People's Hospital2026-09-28
      Conventional vs Biologic Therapy in Pediatric IBDMesalamine—Not yet recruitingAssiut University2026-09-14
      Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseMesalamineNot applicableRecruitingAnabio R&D2026-09-02
      Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative ColitisMesalaminePhase 1 / Phase 2Enrolling by invitationAllama Iqbal Medical College2026-08-26
      Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCMesalaminePhase 4Not yet recruitingSir Run Run Shaw Hospital2026-08-24
      ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch SurgeryMesalaminePhase 4Not yet recruitingUniversity Hospital, Linkoeping2026-08-19
      ND-12 Combined With H-6 for Adult Chronic Inflammatory DiarrheaMesalamineEarly phase 1RecruitingThe Second Hospital of Nanjing Medical University2026-08-17
      The Effect of Nicorandil on Rheumatoid Arthritis PatientsSulfasalazinePhase 2 / Phase 3RecruitingAin Shams University2026-07-28
      Study of ECC4703 With Sulfasalazine and PitavastatinSulfasalazinePhase 1RecruitingEccogene2026-07-24
      AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative ColitisMesalamineNot applicableNot yet recruitingENBIOSIS BIOTECHNOLOGIES2026-06-02
      Palmitoylethanolamide in Ulcerative ColitisMesalamineNot applicableRecruitingAin Shams University2026-05-27
      Venlafaxine as Adjunct Therapy in Rheumatoid ArthritisSulfasalazinePhase 2Not yet recruitingAin Shams University2026-03-27
      Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With SulfasalazineSulfasalazine—RecruitingKlavs Würgler Hansen2026-02-18
      Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under ImmunomodulatorsSulfasalazinePhase 4RecruitingUniversity of Sao Paulo General Hospital2025-12-12
      Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastySulfasalazinePhase 2RecruitingNYU Langone Health2025-08-24
      "Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"SulfasalazinePhase 2 / Phase 3RecruitingUniversity of Guadalajara2025-04-08
      Implantable Microdevice In Primary Brain TumorsMeclofenamic acidEarly phase 1RecruitingOliver Jonas2019-10-23
      Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor PrimaryMeclofenamic acidNot applicableActive, not recruitingMemorial Sloan Kettering Cancer Center2015-04-29

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Asthma
      0.58
      Proctitis
      0.50
      Crohn disease
      0.38
      Arthritic joint disease
      0.37

      Genes and Related Targets

      Complexes and families that share a gene with this target
      Genes
      ALOX5

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL215, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P09917, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.